Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

677 results

Medicine European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Orphan designations Remove Orphan designations filter Direct healthcare professional communication Remove Direct healthcare professional communication filter

Medicine type Accelerated assessment Remove Accelerated assessment filter Additional monitoring Remove Additional monitoring filter Orphan medicine Remove Orphan medicine filter

Sort by

List item

Human medicine European public assessment report (EPAR): Kyprolis (updated)

carfilzomib, Multiple Myeloma
Date of authorisation: 19/11/2015, , , Revision: 19, Authorised, Last updated: 07/05/2021
List item

Human medicine European public assessment report (EPAR): COVID-19 Vaccine Moderna (updated)

CX-024414 (single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2), COVID-19 virus infection
Date of authorisation: 06/01/2021, , , Revision: 2, Authorised, Last updated: 07/05/2021
List item

Human medicine European public assessment report (EPAR): COVID-19 Vaccine Janssen (updated)

adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein (Ad26.COV2-S), COVID-19 virus infection
Date of authorisation: 11/03/2021, , , Revision: 2, Authorised, Last updated: 07/05/2021
List item

Human medicine European public assessment report (EPAR): Ketoconazole HRA (updated)

Ketoconazole, Cushing Syndrome
Date of authorisation: 18/11/2014, , , , Revision: 10, Authorised, Last updated: 07/05/2021
List item

Human medicine European public assessment report (EPAR): Vaborem (updated)

meropenem trihydrate, vaborbactam, Urinary Tract Infections, Bacteremia, Bacterial Infections, Respiratory Tract Infections, Pneumonia, Pneumonia, Ventilator-Associated
Date of authorisation: 20/11/2018, , Revision: 4, Authorised, Last updated: 07/05/2021
List item

Human medicine European public assessment report (EPAR): Tegsedi (updated)

inotersen sodium, Amyloidosis
Date of authorisation: 05/07/2018, , , , Revision: 7, Authorised, Last updated: 06/05/2021
List item

Human medicine European public assessment report (EPAR): Jinarc (updated)

Tolvaptan, Polycystic Kidney, Autosomal Dominant
Date of authorisation: 27/05/2015, , Revision: 16, Authorised, Last updated: 06/05/2021
List item

Human medicine European public assessment report (EPAR): Kaftrio (updated)

ivacaftor, tezacaftor, elexacaftor, Cystic Fibrosis
Date of authorisation: 21/08/2020, , , Revision: 3, Authorised, Last updated: 06/05/2021
List item

Human medicine European public assessment report (EPAR): Flixabi (updated)

infliximab, Spondylitis, Ankylosing, Arthritis, Rheumatoid, Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Psoriasis
Date of authorisation: 26/05/2016, , , Revision: 17, Authorised, Last updated: 06/05/2021
List item

Human medicine European public assessment report (EPAR): Jyseleca (updated)

filgotinib maleate, Arthritis, Rheumatoid
Date of authorisation: 24/09/2020, , Revision: 1, Authorised, Last updated: 05/05/2021
List item

Human medicine European public assessment report (EPAR): Daurismo (updated)

Glasdegib maleate, Leukemia, Myeloid, Acute
Date of authorisation: 26/06/2020, , , Revision: 2, Authorised, Last updated: 05/05/2021
List item

Human medicine European public assessment report (EPAR): Translarna (updated)

Ataluren, Muscular Dystrophy, Duchenne
Date of authorisation: 31/07/2014, , , , Revision: 19, Authorised, Last updated: 05/05/2021
List item

Human medicine European public assessment report (EPAR): Inhixa (updated)

enoxaparin sodium, Venous Thromboembolism
Date of authorisation: 15/09/2016, , , Revision: 18, Authorised, Last updated: 05/05/2021
List item

Human medicine European public assessment report (EPAR): Cabometyx (updated)

cabozantinib (s)-malate, Carcinoma, Renal Cell
Date of authorisation: 09/09/2016, , Revision: 11, Authorised, Last updated: 05/05/2021
List item

Human medicine European public assessment report (EPAR): Aybintio (updated)

bevacizumab, Colorectal Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms
Date of authorisation: 19/08/2020, , , Revision: 3, Authorised, Last updated: 05/05/2021
List item

Human medicine European public assessment report (EPAR): Evoltra (updated)

clofarabine, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Date of authorisation: 29/05/2006, , , Revision: 30, Authorised, Last updated: 04/05/2021
List item

Human medicine European public assessment report (EPAR): Ninlaro (updated)

ixazomib citrate, Multiple Myeloma
Date of authorisation: 21/11/2016, , , , Revision: 10, Authorised, Last updated: 30/04/2021
List item

Human medicine European public assessment report (EPAR): Shingrix (updated)

Recombinant varicella zoster virus glycoprotein E, Herpes Zoster
Date of authorisation: 21/03/2018, , Revision: 6, Authorised, Last updated: 30/04/2021
List item

Human medicine European public assessment report (EPAR): Dacogen (updated)

Decitabine, Leukemia, Myeloid
Date of authorisation: 20/09/2012, , Revision: 14, Authorised, Last updated: 30/04/2021
List item

Human medicine European public assessment report (EPAR): Onivyde pegylated liposomal (previously known as Onivyde) (updated)

irinotecan anhydrous free-base, Pancreatic Neoplasms
Date of authorisation: 14/10/2016, , Revision: 8, Authorised, Last updated: 29/04/2021
List item

Human medicine European public assessment report (EPAR): Comirnaty (updated)

Single-stranded, 5’-capped messenger RNA produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2, COVID-19 virus infection
Date of authorisation: 21/12/2020, , , Revision: 6, Authorised, Last updated: 29/04/2021
List item

Human medicine European public assessment report (EPAR): Ocrevus (updated)

ocrelizumab, Multiple Sclerosis
Date of authorisation: 08/01/2018, , Revision: 11, Authorised, Last updated: 29/04/2021
List item

Human medicine European public assessment report (EPAR): Keytruda (updated)

Pembrolizumab, Melanoma, Hodgkin Disease, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Urologic Neoplasms, Squamous Cell Carcinoma of Head and Neck
Date of authorisation: 17/07/2015, , Revision: 33, Authorised, Last updated: 29/04/2021
List item

Human medicine European public assessment report (EPAR): Lorviqua (updated)

Lorlatinib, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 06/05/2019, , , Revision: 5, Authorised, Last updated: 29/04/2021
List item

Human medicine European public assessment report (EPAR): Blincyto (updated)

blinatumomab, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Date of authorisation: 23/11/2015, , , Revision: 12, Authorised, Last updated: 29/04/2021